Astragaloside IV Attenuates Angiotensin II-Induced Inflammatory Responses in Endothelial Cells: Involvement of Mitochondria
Open Access
- 1 March 2025
- journal article
- research article
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 3951-3967
Abstract
Background: Angiotensin II (Ang II)-triggered endothelial inflammation is a critical mechanism contributing to Ang II-related cardiovascular diseases. The inflammation is highly correlated with mitochondrial function. Although astragaloside IV (AS-IV), a primary bioactive ingredient extracted from the traditional Chinese medicine Astragalus membranaceus Bunge that can effectively treat numerous cardiovascular diseases, posses the actions of antiinflammation and antioxidation in vivo, limited data are made available on the impacts of AS-IV on mitochondrial function in endothelial inflammation triggered by Ang II. This study was performed to evaluate the in vitro actions of AS-IV on Ang II-triggered inflammatory responses in endothelial cells, and to further clarify the potential role of mitochondria in the actions. Methods: Human umbilical vein endothelial cells (HUVECs) were preincubated with AS-IV and then exposed to Ang II for 12 h. Results: The exposure of HUVECs to Ang II triggered cytokine and chemokine production, the upregulation of adhesive molecules, monocyte attachment, and nuclear factor-kappa B activation. Additionally, our results showed that the inflammatory responses triggered by Ang II were associated with the impairment of mitochondrial function, as evidenced by the reductions of mitochondrial membrane potential, ATP synthesis, and mitochondrial complexes I and III activities. Moreover, the concentrations of malondialdehyde, cellular reactive oxygen species, and mitochondrial superoxide enhanced after HUVECs challenged with Ang II, which were concurrent with the decreases in total superoxide dismutase (SOD) and its isoenzyme activities such as Mn-SOD. These Ang II–induced alterations were reversed by preincubation with AS-IV. Conclusion: Our data indicate that AS-IV attenuates Ang II-triggered endothelial inflammation possibly via ameliorating mitochondrial function.Keywords
This publication has 50 references indexed in Scilit:
- PINK1/Parkin pathway-mediated mitophagy by AS-IV to explore the molecular mechanism of muscle cell damageBiomedicine & Pharmacotherapy, 2023
- Triptolide Alleviates Oxidized LDL-Induced Endothelial Inflammation by Attenuating the Oxidative Stress-Mediated Nuclear Factor-Kappa B PathwayCurrent Therapeutic Research, 2022
- Cardiovascular Risk Factors and Prevention: A Perspective From Developing CountriesCanadian Journal of Cardiology, 2021
- Vascular endothelial cell specification in health and diseaseAngiogenesis, 2021
- Decreased Hepatocyte Autophagy Leads to Synergistic IL‐1β and TNF Mouse Liver Injury and InflammationHepatology, 2020
- Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects2020
- Astragaloside IV reversed the autophagy and oxidative stress induced by the intestinal microbiota of AIS in miceJournal of Microbiology, 2018
- TRPV1 agonism inhibits endothelial cell inflammation via activation of eNOS/NO pathwayAtherosclerosis, 2017
- 30 Years of NF-κB: A Blossoming of Relevance to Human PathobiologyCell, 2017
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983